Founded in 1994, Omeros has evolved from a GPCR discovery pioneer into a commercial entity with a strategic focus on the complement system. Its key achievement is the FDA approval of OMIDRIA for cataract surgery, while its primary value drivers are the late-stage investigational drugs narsoplimab for HSCT-TMA and OMS906 for PNH. The company's strategy involves prioritizing these high-potential clinical programs, seeking regulatory approvals and partnerships, and managing its significant debt burden to achieve sustainable growth.
ImmunologyHematologyNephrologyOphthalmology
Technology Platform
Proprietary platforms targeting the complement system, specifically the lectin pathway via MASP-2 inhibition (narsoplimab) and MASP-3 inhibition (OMS906), and a legacy GPCR discovery platform that was divested.
Funding History
3
Total raised:$317M
Debt$125MAthyrion Capital Management
PIPE$150MUndisclosed
IPO$42MUndisclosed
Opportunities
First-ever approval in HSCT-TMA with narsoplimab could create a high-value orphan drug franchise.
The novel MASP-3 mechanism of OMS906 offers a differentiated entry into the large and growing complement inhibitor market for PNH and other disorders.
Successful data in IgA Nephropathy could tap into a multi-billion dollar chronic kidney disease market.
Risk Factors
The company faces existential regulatory risk with the pending BLA decision for narsoplimab.
A substantial debt burden and limited cash runway create significant financial liquidity risk.
Intense competition in complement-mediated diseases from large, well-capitalized players poses a major commercial challenge.
Competitive Landscape
In HSCT-TMA, narsoplimab would be a first-in-class agent with no direct competitors. In IgA Nephropathy and PNH, it faces entrenched and emerging competitors from large pharma and biotech, requiring superior efficacy or a partnership to achieve meaningful market share.
